Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)
* Swedish orphan biovitrum Q2 total revenue was SEK 1,639 mln (1,469)
* Says company and Raffensperger, have come to the agreement that Raffensperger will leave the company to pursue other opportunities. Source text for Eikon: Further company coverage: (Stockholm Newsroom)
* Sobi keeps the Partner Products business area as an integral part of the company
* Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH
* Says Q1 revenues grew 10 per cent overall, and by 47 percent adjusted for the one-time credit of SEK 322 million received in Q1 2016.